List of Therapeutic Companies in Canada - 183

35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Cardiometabolic Disease and Obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands. We believe in connecting rigorous science with our innate sense of urgency to rapidly generate breakthrough therapies for patients in need of a better quality of life. Our beautiful R&D and office facilities are located in the heart of Montreal, Canada, where a diverse team of industry professionals work together to execute on our mission to serve patients in need. If our corporate culture and dedication to patients resonate with you, we invite you to join our team: https://35pharma.com/careers/

Collagen fibers produced using our patented dry-spinning technology recapitulate the biomechanical and biochemical properties of natural collagen structures. With a fully automated manufacturing system, we are the first to produce collagen fibers at commercial scales for a variety of tissue engineering applications, including additives for 3D bioprinting and hydrogels, and cellular scaffolds for 2D and 3D cell and tissue culture.

Founded in 2017, 48Hour Discovery (48HD) has a powerful technology platform for peptide-based drug discovery. We are reducing the cost, time, and risk of developing new therapies with our innovative target screening strategy to quickly identify the best and most promising drug leads.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health.

We apply proprietary computational tools to bacterial metabolomic and genomic data in order to identify, isolate, and assay novel drug-like small molecules in high-throughput to expedite the search for medicines that will better protect us from a wide spectrum of diseases.

AGADA Biosciences is a biotechnology company that specializes in providing expert assistance with drug development programs in neuromuscular disease, offering pre-clinical trials in mouse models and human clinical trial support.

Akseera, is a science driven, innovative, and distinctive company that draws on the unique experiences of our team to bring ingenious solutions that address unfulfilled medical needs globally. We endeavor to do this independently and in collaboration with world class institutions to help improve lives.

Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies. Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Privately-held Montreal-based biotechnology company Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. Currently having one clinical-stage program with phase I data. Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology. Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline. Established strategic partnerships to access mAb generation, humanization, antibody-drug conjugates, and CHO production technologies

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) is a clinical-stage pharmaceutical development company. Our unique drug repurposing strategy enables us to discover new therapeutic uses for existing drugs. This business model lowers investment, risk, and research periods while increasing active patent life. Twitter: @AlgernonPharma Facebook: @AlgernonPharmaceuticals

Built on 30+ years of foundational expertise, Allarta’s proprietary platform is designed to overcome immune rejection, prevent cell escape and safely deliver cell and stem cell therapies. Our lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

Andira Pharmaceuticals is a private healthcare company delivering purposeful innovation to improve lives and address critical illness. We are pioneering a new generation of therapeutics by leveraging the power of natural drug substances to deliver urgently-needed solutions for both consumer and hospital-based medical indications.​ Andira’s lead products address highly prevalent medical indications in three areas: Hospital-Acquired Infection Oncology Dermatology Our groundbreaking technologies originate from a validated pharmacotherapeutic platform – allowing us to uncover pharmacologic synergy between natural drug substances and existing medical treatments. Our discoveries are further optimized through careful pre-clinical research to create new therapies with dramatically improved efficacy and safety.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Aquinox Pharmaceuticals is a biopharmaceutical company that focuses on drug development and conducting clinical trials in the healthcare industry.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.

Atorvia is a pre-clinical stage biopharmaceutical company on a mission to transform outcomes for patients with organ failure, starting with the kidney. Headquartered in Ottawa, ON, Atorvia is advancing a pipeline of technologies that will disrupt the existing organ failure landscape and transform outcomes for patients. Atorvia's lead program is focused on critical protein:protein interactions that trigger cell death and kidney failure. A first-in-class synthetic peptide therapeutic is in development with an initial indication in Acute Kidney Injury (AKI). AKI is a common and often fatal condition that leaves surviving patients with long term morbidities and can lead to chronic kidney disease, end stage renal disease, stroke & myocardial infarction. There is currently no treatment available.

We pursue promising science to address some of the toughest challenges in autoimmune disease. Community guidelines: 1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 2. Unless posts are from an official Aurinia social media handle, none of the posts or comments are posts made by us, but from members of the public. We take no responsibility for comments or posts made by third parties on our channels, and the content of those comments or posts (including any opinions or statements) may not reflect our views, and are the responsibility of the individual posting them. 3. We may discuss medical and health-related topics on our social media feeds. The content we post, and any associated content shared by other users, should not be taken as medical advice. We ask that you refrain from soliciting or posting medical advice on this feed. For advice and information related to your health, please seek advice from your doctor or other healthcare professional. 4. Aurinia reserves the right to remove any content or comments that violate these guidelines or are otherwise deemed inappropriate. We may block or ban users who repeatedly violate these guidelines or engage in disruptive behavior. To learn more, visit: https://www.auriniapharma.com/aurinia-community-guidelines US-NA-2300266 08/23

Avir Pharma is a wholly-owned, privately-held Canadian pharmaceutical company whose mission is to enhance the lives of Canadians through the acquisition, in-licensing and co-development of innovative, specialty pharmaceutical products. Avir Pharma is an affiliate of the Laboratoire Riva Group, an established company with over 40 years of experience in manufacturing, distributing and promoting pharmaceutical products in the Canadian marketplace.

Cancer doesn’t wait — so we shouldn’t either. At Avitia, we’re making sure that clinical labs and oncologists everywhere have the tools they need to diagnose, as well as treat cancer faster. Our AI/ML technology ensures partners have cost-effective NGS-based molecular testing solutions that provide rapid turnaround times. Now, we empower healthcare teams to skip the delays and focus on what matters — personalized patient care. From pinpointing cancer mutations to streamlining clinical trial access, we’re here to make precision oncology accessible for every community and improve patients’ quality of life. Let’s transform cancer care together. Le cancer n’attend pas, et nous ne devrions pas non plus attendre. Chez Avitia, nous veillons à ce que les laboratoires cliniques et les oncologues du monde entier disposent des outils dont ils ont besoin pour diagnostiquer et traiter le cancer plus rapidement. Notre technologie IA/ML garantit à nos partenaires des solutions de tests moléculaires NGS rentables qui offrent des délais d’exécution rapides. Désormais, nous permettons aux équipes de soins de santé d’éviter les retards et de se concentrer sur ce qui compte : des soins personnalisés aux patients. De l’identification des mutations cancéreuses à la rationalisation de l’accès aux essais cliniques, nous sommes là pour rendre l’oncologie de précision accessible à toutes les communautés et améliorer la qualité de vie des patients. Transformons ensemble les soins contre le cancer.

Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers to better prioritize patients by medical urgency, spend less on management and logistics and ultimately save more lives.

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders. Our vision is to take the fear out of psychedelics by producing non-hallucinogenic medicines that will be the solutions to treat the wide range of unmet mental health conditions like anxiety, depression, PTSD, & migraine

Biocure Technology Inc. is a biopharmaceutical company comprised of leading scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing Biosimilar technologies for cancer treatment. The CAR T-cell cancer therapy space is one of the most innovative cancer treatments currently in the market and is seeing huge global interest. Founders and management are driven by a social agenda aimed at providing a global answer to highly priced biological medicines that remain outside the reach of common people. The company has unique scientific and execution skills to address the high barriers of CAR-T cell therapy and Biosimilar technologies, therefore is well positioned to gain leadership in the rapidly growing market of CAR T-cell cancer therapy.

Cardiovascular solutions without compromise. BioIntegral Surgical, Inc. is focused on all-biological cardiovascular implants which are designed to last the lifetime of the patient. All BioIntegral Surgical devices are backed by a lifetime warranty, the only of its kind in the medical device industry. Balancing the most durable designs, biocompatible materials and quickest to implant devices, the implants are meant to eliminate the ordinary compromises and short-comings of other devices. Other devices don’t have permanently fixed tissue, leach toxic residuals, use synthetic materials or have cheaper-to-manufacture designs which compromise the redistribution of force and longevity. Company core values ------------------------------ Excellence. We commit to make the best, high-quality devices available globally Initiative. We value initiative to improve the capabilities of the company although not at the expense of quality Integrity. We strive for integrity in our decisions and products Ownership. We instill a sense of ownership for each employee Education. We aim to educate each other so we can make the best decisions and produce the best results together

Biolyse Pharma specializes in manufacturing and developingof sterile oncology drugs.- Currently produces Paclitaxel for the treatment of cancer, known for its mild side effects when compared to similar chemotherapy agents- Supplies 80 per cent of the Canadian demand for Paclitaxel

BioNxt Solutions is a leading bioscience company that rapidly innovates drug formulations, diagnostics, drug delivery, and neurological drugs.

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX™ immune-educating delivery technology platform and our HapTenix© neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© neoantigen tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. BioVaxys is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.

Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.

Our team at BriSTAR Immunotech is dedicated to the development and commercialization of innovative T cell immunotherapy products for the treatment of cancer and viral infections with urgent unmet medical needs. We leverage our proprietary STAR-T platform to engineer next-generation T cell therapies for treating hematological malignancies and solid tumors. The STAR-T platform combines the advantages of CAR-T (Chimeric Antigen Receptor T-Cell immunotherapy) and TCR-T (T Cell Receptor T-cell immunotherapy) to produce mono- or bi-specific T cell therapies. The promising antitumor actions of STAR-T cell therapies include better antigen sensitivity and stronger tumor infiltration. These properties are critical for achieving better responses in cancer patients, especially in treating solid tumors.

Cardiol Therapeutics Inc. (NASDAQ: CRDL | TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

Headquartered in Kickland, Quebec, ChitogenX Inc. (formally Ortho Regenerative Technologies Inc.) is a clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. ORTHO-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. ORTHO-R can be directly and easily applied to the site of injury by a surgeon during a routine operative procedure with minimal disruption to length of surgery. ORTHO-R is currently the object of an ongoing U.S. Phase I/II clinical trial for rotator cuff tear repair in 10 U.S. based clinical centers. Other formulations are being developed to leverage the technology's performance characteristics such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease. Further information about Chitogenx is available on the Company's website at www.chitogenx.com and on SEDAR at www.sedar.com.

Clearmind Medicine develops novel psychedelic medicines to solve widespread—yet under-served—health problems. With a strong medical management and IP-protected.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Covalon is a leading provider of compassionate care solutions that help patients heal faster and live better. We are a patient-driven medical device company, with a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention and medical device coatings. We offer innovative, gentler and more compassionate options for patients to heal with less infections, less pain and better outcomes, because we care.

CryoStasis is a biotech company specializing in bio-preservation of cells, tissues and organs. Located in Ottawa and based on 30 years of pioneering research in the Canadian Arctic, we have developed a method that overturns the long-held belief that biological material must be frozen for its function to be preserved. By using rationally designed cryoprotectants (Woolii™Cool media) along with temperature and pressure management systems (Woolii™Pod), our platform drops temperatures well below freezing, halting cellular metabolism WITHOUT TURNING WATER INTO ICE. Maintaining sub-zero, unfrozen conditions induces stasis (indefinite preservation) while avoiding the dramatic loss of cell function, therapeutic potency and manufacturing yield that occur as a result of freeze-thaw damage. CryoStasis works with BioPharma, CDMOs and research institutions to help ensure life-changing cell & gene therapies can be produced at-scale economically, and reach patients whenever / wherever they are needed.

Cybin is a biotechnology company that focuses on developing psychedelic therapeutics for mental health treatment.

DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.

Dalton is a contract pharmaceutical manufacturer which provides integrated chemistry, development, and manufacturing to biotechnology and pharmaceutical clients around the world. In its 42,000 sq. ft. facility, Dalton operates - cGMP manufacturing of Active Pharmaceutical Ingredients (APIs), - sterile injectables, - finished drug products in vials or syringes - solid oral dosage forms. APIs can be produced in gram to kilogram quantities, including sterile APIs. Dalton contract capabilities can support you at any stage of the regulatory process (Phase I, II, III, or commercial). Development services include - chemistry and process development, - medicinal chemistry, - custom drug conjugation, - targeted drug delivery systems, - analytical method development and validation, - ICH stability testing, - formulation, and - polymorphism screening. Dalton also supports the industry's pharmaceutical research programs with a catalog of 2,500 reference standards, building blocks, metabolites, and impurities with its Dalton Research Molecules division.

Defence Therapeutics is a publicly-traded (CSE: DTC, OTCQB: DTCFF, FSE: DTC) clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

VAL-083 is a small-molecule chemotherapeutic that benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer therapy overseas. Efficacy has been demonstrated in a range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Del Mar Pharma has filed an IND with the USFDA to initiate a dose-escalating Phase II clinical trial in refractory GBM, a major market opportunity.

Derm-Biome Pharmaceuticals, Inc. is a Vancouver-based preclinical biopharmaceutical company founded in 2018 focused on developing and advancing safe and effective topical therapies for inflammatory skin disease, acne, and other skin conditions. The company is also involved in research related to skin cancer and healthy aging.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

enGene Inc. has developed a highly flexible nucleotide (DNA and RNAi) delivery technology that targetsmucosal tissues and can be used to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others.

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen.

Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications.

ESSA’s initial focus is in the treatment of prostate cancer. Prostate cancer is a male hormone (androgen) driven malignancy, and six decades of drug development have resulted in continuous improvements in anti-androgen therapy. Yet resistance commonly develops to drugs. ESSA had developed a new class of drugs, the “anitens”. These drugs interrupt androgen-driven biology in a novel manner and are active even in the setting of resistance to current anti-androgen therapies.

ExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand stem cells.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antimicrobial drug candidates that will address the challenge of antimicrobial resistance (AMR). Fedora is interested in exploring partnerships and/or licensing agreements with industry and academia to support its growing pipeline of product candidates. For more information on business development opportunities at Fedora, please contact Fedora at info@fedorapharma.com.

Feldan is a clinical-stage pharmaceutical company that specialized in the development of innovative treatments based on intracellular delivery. At the heart of our mission is the Feldan Shuttle, a unique peptide-based technology that provides access to intracellular targets beyond the reach of existing drugs, opening unprecedented opportunities to treat a wide range of diseases, notably respiratory and skin diseases. Since its inception, Feldan has been committed to innovation and redefining the quality of life for patients by improving the standard of care. As a team, we are driven to expand the horizons of therapeutic delivery and we take pride in our collective sense of accountability, collaboration and commitment to strive for excellence while having fun at work. Our dynamic team of experts in chemical engineering, cell biology, clinical development and business is united by our corporate culture and core values: ownership, teamwork, and fun. _ Feldan est une entreprise pharmaceutique spécialisée dans le développement de traitements innovants basés sur l’administration intracellulaire. Au cœur de notre mission se trouve le Feldan Shuttle, une technologie unique à base de peptides qui donne accès à des composantes intracellulaires hors de portée des médicaments existants, offrant ainsi des perspectives sans précédent pour le développement d’une nouvelle génération de traitements, notamment pour des maladies affectant la peau et les poumons. Depuis sa création, Feldan met l'accent sur l'innovation et a pour but de redéfinir la qualité de vie des patients en faisant évoluer les normes de soins. En tant qu’équipe, nous sommes motivés à étendre les possibilités de livraison intracellulaire et fiers de notre sens de l’engagement, de la collaboration et de l’excellence. Notre équipe d'experts en génie chimique, biologie cellulaire, développement clinique et affaires est unie par notre culture d'entreprise et nos valeurs: appropriation, travail d'équipe et plaisir.

We develop clinically driven, first-in-class, tissue-specific therapeutics from human diseased tissue to treat specific fibrotic disease populations.

We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases. Dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases, our company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and an exclusive global license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Acasti Pharma Inc. (ACST) is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company's novel drug delivery technology platforms provide a versatile and flexible capability to develop and manufacture a wide range of pharmaceutical dosage forms, including oral, injectable, and topical, as well as various products to treat rare and orphan diseases. Acasti's lead product candidate is CaPre, an omega-3 phospholipid therapeutic for the treatment of severe hypertriglyceridemia, a condition that affects an estimated one third of the U.S. population. The Company is also developing a medical food, Onemia, for the treatment of patients with hypertriglyceridemia. Acasti Pharma is headquartered in Laval, Quebec, Canada.

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes. The Company is focused on well-understood diseases that are poorly served by available therapies or have no approved therapies. Acasti is initially targeting three underserved orphan diseases - Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN) – all with sizable patient populations and significant market opportunity. The Company's three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents.

Based on world-leading technology, we are developing a unique ultrasound helmet that is as portable as it is precise. Our first disease target: Alzheimer’s disease.

Pioneering next-gen precision therapeutics for diseases stemming from microtubule dysfunction, such as neuropathies and cardiovascular diseases.

We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells. Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 platform technology.

Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments.

The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. Who We Are HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), Dorval (Montreal, Quebec), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug’s originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada’s regulations. Our Goal/Our Mission HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.

IFOWONCO uses advanced computational modelling techniques coupled with state of the art machine learning to rapidly identify and optimize drug candidates.

Immune Biosolutions is a clinical stage biotech company specializing in discovering and engineering avian and human antibodies for therapeutic and diagnostic applications. Our cutting-edge techniques, including phage display and single B cell screening technologies, enable us to engineer custom-fit immunotherapeutic agents. Our discovery platform is available for biotech and pharma partners, providing access to highly conserved mammalian lineage targets and opening up new possibilities for innovative therapeutics. Our biomanufacturing capacity, which has already supported successful internal clinical trials, is also available for partners in a fee-for-service model. Our internal pipeline includes several discovery programs for various cancer and infectious disease indications. Through our platform, we generate diverse antibodies with high binding affinity and novel paratopes, paving the way for exciting new approaches to treating difficult proteins.

ImmVue Therapeutics is a company that develops small-molecule screen KISMEHT to identify allosteric modulators of the kinase family. Its lead compounds use lymphocytes and aim to revert patients to their vibrant selves with innovative medicines that target novel mechanisms to revitalize their immune system.

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Nasdaq: INM

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

IntelliStem, Inc. is a clinical-stage biotech that develops innovative cellular immune cancer therapy approaches. The Company has demonstrated the...

Acquired by Novo Nordisk in 2023. Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

We’re at the forefront of next-generation antibody drug conjugate discovery, thanks to our innovative, in-house developed Smart AntibodiesTM delivery technologies and utilization of the next-generation smart Payloads such as oligonucleotides, PROTAC, and peptides. Our mission? To unlock the vast therapeutic potential of the antibody drug conjugate modality. To achieve this, we’re engaged in expansive global collaborations with leaders in therapeutic research.

Izotropic is a Medical Imaging company that specializes in making Breast CT an indispensable tool for improving breast cancer outcomes.

Juno Pharmaceuticals Canada sources, develops, and delivers life saving specialized pharmaceutical products for Canadian patients. Our colleagues work with trusted partners to co-develop novel drug delivery mechanisms that satisfy untapped market demand, first to market generic products, biosimilar offerings, and patent challenge strategies. Juno's portfolio consists of both branded and generic drug assets in multiple presentation forms including injectable drugs (vials, amps, & pre filled syringes), complex biosimilars, ophthalmic products, oral does tablets and capsules, prescription dermatology topicals, and other unique dosage systems. Our team have deep roots into the Canadian hospital space, retail pharmacy market, specialty channels, and a robust B2B platform. In addition, Juno Canada has recently embarked with product sourcing in the animal health space and remain focused on opening new delivery channels and customer groups to facilitate supply for Canadian patients. Juno is proud to supply 5 molecules deemed medically necessary by the World Health Organization on their critically essential medications list, and we are actively pursuing export opportunities to countries in need of our critical medications. To learn more about Juno Pharmaceuticals Canada please contact us at communications@junopharm.com For sales enquiries contact us at sales@junopharm.com

Kapoose Creek Bio is a Canadian biotech company using AI technologies to uncover small molecule medicines from nature with unprecedented speed and scale. Our R&D efforts are supported by off-grid research facilities in the hunt for undiscovered chemistry in environments of unique biodiversity. We have developed a platform – unEarth Rx – that integrates phenotypic screening with advanced machine and deep learning to accelerate the identification of high-quality drug leads and simultaneously determine their mechanism of action. The result is a comprehensive, data-rich, functional map of nature's chemistry for accelerated discovery and development of new small molecule medicines. We are building a diversified portfolio of stakes in the next generation of critical medicines, focusing our platform on neuroscience, cancer and infectious disease. Currently our development pipeline is concentrated on lead assets with exciting potential in neurological indications.

KisoJi is dedicated to developing multi-specific antibody technologies and therapeutics that improve outcomes in oncology.

Knight Therapeutics Inc. (TSX:GUD) is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and select international markets.

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis. The company is advancing promising research in small molecules for a range of diseases related to fibrosis including respiratory, liver and renal diseases. Through a separate business unit called Prometic, the company also focuses on the use of bioseparation technologies to isolate and purify biopharmaceuticals derived from human plasma.

LineaBio's mission is to enable the cell and gene therapy industry by providing access to high-quality, off-the-shelf iPSC lines manufactured under GMP that streamline drug product manufacturing. By allowing therapeutic developers to cut costs and accelerate timelines for GMP reprogramming, LineaBio strives to achieve its vision of making cell therapy universally accessible and affordable. Founded in 2023 by parent companies CCRM and OmniaBio, LineaBio draws on a team of iPSC experts that have been developing an iPSC platform for more than a decade.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and distribution of pharmaceutical products. The company has completed the acquisition of Virage Santé and has entered into an exclusive distribution agreement with Fera Pharmaceuticals to alleviate drug shortage in U.S. hospitals. LSL Pharma Group Inc. is listed on the TSX Venture Exchange under the ticker symbol LSL.V.

Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to address hypertriglyceridemia and other metabolic diseases.

Mati Therapeutics is a healthcare company that specializes in developing a proprietary ophthalmic drug delivery system using punctal plugs for introducing therapeutic agents.

The mDETECT tests are highly specific and sensitive blood tests that monitor c tumour burden in cancer (metastatic) patients using targeted methylation marks in circulating tumour DNA (ctDNA). mDETECT can accurately and rapidly determine cancer relapse, progression, and response to therapy to help extend the lives of patients.

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Mesentech is a clinical stage biotechnology company developing novel medicines that selectively distribute to the intended site of action. MES1022 is a clinical stage program for bone-repair being developed for 3 indications. Our preclinical pipeline includes novel compounds targeting bone-cancers.

Metabolica Health Inc. is a development stage biotechnology firm discovering and developing innovative treatments for diabetes and obesity.

ME Therapeutics is a Biotechnology company that specializes in Immuno Oncology, focusing on treating previously untreatable cancers by targeting the immune system.

Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health and wellbeing. We manufacture a wide range of biological materials for the global diagnostics industry, notably antigens used in immunoassays and Quality Assessment Products (QAPs™). In 2021 we launched our first Viral Transport Medium, branded as DxTM. Microbix’s business of producing high-quality viral and bacterial preparations stems from over three decades of experience in the field, including strain selection, reliable and efficient organism culture at scale, purification, and pathogen inactivation. As a result of Microbix’s expertise, its products have received widespread and longstanding customer acceptance, with continuing growth in demand. Microbix’s current catalogue of biological preparations covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted, and insect-borne diseases. Microbix also applies its biological expertise to develop other innovative and proprietary technologies and products. Our development project pipeline currently includes Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots.

MicroSintesis wants to change the way the world fights diseases. Our vision is a world having more creative and effective options to fight diseases and their consequences. To do so, we need to look elsewhere. There is a growing body of evidence that supports micro-organisms having the ability to communicate with one another. Quorum sensing is the source of microbiome's balance and helps avoid dysbiosis leading to diseases or infections. MicroSintesis wants to revolutionize human and animal welfare through harnessing microbiome's full potential. Amongst immediate challenges, we find antibiotic resistance. This has become an increasing threat to life. While the emergence of new resistant pathogens is accelerating, the ones already there are strengthening. Medical professionalss want to reduce the use of antibiotics, but evidently will not settle for less effectiveness. MicroSintesis is not just another probiotic company. We go a step ahead, strive for discovery and strongly believe that providing health practitioners with a response to antimicrobial resistance should find its way through science. Our solutions leverage years of worldwide scientific discoveries. We believe that our unique patented metabolite is at the heart of microbiome's communication system. MicroSintesis pioneers the creation of a new generation of science-based microbiome and health technologies. We are committed to lead microbiome's research, discover proven & effective alternative to antibiotics, impact long standing health challenges, improve human and animal welfare and promote access to new and effective health solutions.

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States.

Cell and gene therapy promises to one day cure any pathology; Modulari-T’s MARC Platform produces the tools to fulfill that promise.

Our proprietary technology focus on the dual functions of pentamidine on controlling the function of a DNA repair enzyme – endo-exonuclease (EE:Trmt2) and specific targets anti-inflammatory/Lipopolysaccharide (LPS) binding. The EE is found in large amounts in cancer cells and its function is to repair DNA breaks that occur when cancer cells proliferate. Blocking this enzyme would cut off cancer growth. With a unique combination of proprietary expertise on EE (Trmt2) and pentamidine, the company is well positioned to develop pentamidine analogs for breakthrough solutions in cancer therapy1-5. Pentamidine is known to be active on cancer cells. The effectiveness and significance of DNA repair process in medicine has most recently been exemplified in 2015 Nobel Prize in Chemistry. The effect of pentamidine as potential anti-inflammatory agent is well documented6,7. However, its development for anti-inflammation application is limited by its cytotoxic effect. With proprietary technology, we are able to identify pentamidine analogs that retains the anti-inflammation activity but reduce cytotoxicity to broaden our scope into Gastro-intestine (GI) condition as well as liver disease.

Morphocell Technologies Inc. is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues targeting liver failure. The Company is a spin-off of the Hepatology and Cell Therapy lab of Sainte-Justine University Hospital Center, in Montreal. Founded in April 2018 on the technology developed by Dr.Paganelli, a pediatric transplant hepatologist and stem cell scientist, Morphocell Technologies aims at bringing to market the first effective treatment for acute, chronic and acute-on-chronic liver failure.

Moss is a disrupter in the consumer healthcare space offering personalized health and gut health solutions guided by genomic data, microbiome data, and clinically validated assessments. Founded in 2018, Moss is a technology and healthcare integrator for personalized health and offers a comprehensive line of probiotics and nutritional supplements.

MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

Naegis Pharmaceuticals is an ophthalmology-focused biopharmaceutical company developing new oral and topical therapies, active in the discovery and development of novel small molecules that target underlying chronic inflammatory processes in eye diseases.

NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases. NTx is delivering tomorrow's genetic medicines, today. For more information, please visit nanovationtx.com.

RM-581, a small molecule in early developpement of a new class (the aminosteroids), demonstrated its ability to block the progression or even reduce the size of cancerous tumours that are difficult to treat with conventional chemothérapy. Le RM-581, une petite molécule en développement préclinique d'une nouvelle classe (les aminostéroïdes), a démontré une capacité à bloquer la progression ou même réduire réduire la taille des tumeurs cancéreuses difficiles à traiter avec la chimiothérapie classique.

NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.

Neurenati develops novel therapies for GI rare diseases

ATGen Canada/NKMax Canada is the Canadian division of NKMax Co Ltd (Korea), a public biotechnology company dedicated to restoring and enhancing overall immune integrity. NK Vue, NKMax’s proprietary blood test for the measurement of immune function, is the first commercially available test that quantifies natural killer cell activity in a small volume of stimulated whole blood. NKMax also develops its proprietary natural killer cell expansion and activation technology as a treatment for a number of cancers and other disorders, and is currently conducting clinical trials in the US and Korea.

Noa Therapeutics is a preclinical biotech company pioneering the development of multimodal therapies. Singular, non-steroidal, small molecules with tunable therapeutic drivers are offered to address complex immune diseases, enabling patients to achieve better outcomes.

Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells.

Notogen is developing a novel biologic regenerative therapy to treat degenerative disc disease (i.e. chronic back and neck pain as a result of degenerating spinal discs). The product, which is pre-clinical and currently undergoing cGMP manufacturing, is an injectable solution that is fast to administer, cost-effecti ... see more

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

OPTITHERA was founded in 2016 and has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries. Based on these clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

Orion is a clinical stage company leveraging a proprietary technology platform to develop next generation therapeutics for effectively targeting G Protein-Coupled Receptors (GPCRs). Orion’s platform enables effectively targeting previously undruggable complex GPCRs. Our pipeline includes 3 next generation therapeutics for cancer including our lead candidate - OB-002 – which is a first-in-class cancer immunotherapy with best-in-class potency.

Welcome to Ostia Sciences, a premier microbiome solutions company that specializes in discovering novel bacterial metabolites with antibacterial, antibiofilm, and immunomodulation activities. Our goal is to isolate beneficial microbes from the human oral microbiome, human breast milk, and fermented food, which are known to be rich sources of ribosomally synthesized and post-translationally modified peptides (RiPPs) and natural products with a range of biological activities.

Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.

Pan-Biome Pharmaceuticals, Inc, is a Vancouver-based preclinical biopharmaceutical company spun out two years ago with a focus on developing safe and highly effective drugs to promote healthy aging and healthspan. We recently developed a new generation of natural product-based small molecule compounds that exhibit a variety of beneficial biological activities with the potential to modulate important pathways that, when altered, can lead to the development of inflammatory, immune and degenerative diseases.

Paradox Immunotherapeutics is an pharmaceutical company developing immunotherapies for rare diseases using a proven-successful immunotherapy drug design platform. We design drugs that harness the body’s own immune system to clear lethal deposits from affected organs and reverse organ damage. Our team has a successful history in designing drug candidates for amyloidosis and taking them from bench to bedside. Using the same platform technology, our lead candidate includes a potential treatment for immunoglobulin light chain (AL) cardiac amyloidosis. Their other discovery pipelines include treatments for chronic renal failure and neurodegenerative diseases. With a team of experts in immunotherapy drug design, they possess an orphan drug discovery platform, termed "The PARADOX Platform" for the potential treatment of ~30 rare diseases, a platform technology which has already sparked the interest of major players in the pharmaceutical industry.

PharmAla Biotech Inc. is a Canadian Biotechnology company dedicated to the research, development, manufacture and sales of MDMA in service to the clinical research community.

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets.

pHLIP, Inc. was founded to bring its proprietary pHLIP® Platform Technology to the clinic, aiming to improve the treatment of diseases where visualization and targeted therapy would be highly advantageous. The possible applications of the technology are wide-ranging, including cancer, inflammation and fibrosis. Our dreams for the improvement of medicine include many possibilities: Imaging of the blood will allow the local circulation to be continuously monitored during surgery. Marking the surfaces of tumor cells will guide efficient and conservative removal of tumors or will activate the immune system to attack the tumor. Targeting of effective agents will alleviate inflammation. Targeted delivery of agents to cells in tumors will broaden the range of therapeutics while suppressing side effects.

Patients need reliable FDA approved cannabinoid treatments. Developing safe and effective cannabinoid formulations with superior drug delivery is our answer.

PlantForm Corporation is a Canadian biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus and other life-threatening illnesses. The company’s vivoXPRESS® plant-based technology platform produces biopharmaceutical products in fully contained greenhouse environments. PlantForm’s pipeline features both innovator and biosimilar products, including: • 3 biosimilar cancer drugs, leading with trastuzumab, a plant-produced version of the breast cancer drug Herceptin® • innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation • innovator antibodies for treatment of Ebola virus (Sudan strain), with financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) • recombinant butyrylcholinesterase (BuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants. PlantForm is interested in establishing partnerships with other companies to develop additional targeted biosimilar and innovator drugs.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide.

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer. On Dec. 27, 2023, Lilly Completes Acquisition of POINT Biopharma.

Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

AN INSIDE OUT APPROACH TO PROSTATE ABLATION Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. Profound's novel technology combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit profoundmedical.com

ProMIS Neurosciences, Inc. is a leading development-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. The company is focused on the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy through the development of antibody therapeutics and diagnostics. ProMIS Neurosciences is publicly traded on the Toronto Stock Exchange.

ProMIS Neurosciences is focused on the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy through the discovery and development of antibodies selective for toxic misfolded proteins driving these diseases.

ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering.

Providence Therapeutics Holdings Inc is a clinical-stage biotechnology company focused on drug development and platform development. The Providence mRNA Medicines platform is comprised of four integrated platforms: 1) mRNA Medicines Platform, 2) NextGen lipid nanoparticles (LNP), 3) Manufacturing Platform and 4) Regulatory Platform. Providence’s mRNA and NextGen LNP platform offer an end-to-end solution for designing codon-optimized ultrapure mRNA that can be formulated in application optimized LNP. The Providence proprietary NextGen LNP, consists of rationally designed lipids that have been tested for suitability for programs in oncology, infectious diseases and gene delivery. Our scalable, efficient platform demonstrates differentiated capabilities in mRNA design, manufacturing, and formulation processes, as well as specific organ and tissue targeting. For more information, please visit providencetherapeutics.com

Psyence (PSYG) is a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well‑being. We have a focus on these conditions in the context of palliative care. Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa. For more information: www.psyence.com

PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system for precise retinal surgery. Our patented next generation ultrafast femtosecond laser ophthalmic treatment will enable treatment for retinal diseases such as age-related macular degeneration (AMD) and glaucoma, for which there is currently no cure. PulseMedica is a company based out of Edmonton, AB, Canada.

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). SSIs aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. The company has initiated three clinical trials in Crohn's disease, ulcerative colitis and lung cancer. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally. We are always interested in talented biotechnology professionals and know that some of the best team members can be found when you’re not looking for them. For Qu, finding the right team member is not about matching a resume to a checklist of skills, it’s about integrity and character. If you have big ideas, love a fast-paced innovative environment and you’re up for the challenge, we want to hear from you. Send us your resume and a detailed cover letter telling us about yourself and how you feel you could contribute.

QurCan Therapeutics (formerly Nanology Labs Inc) is a biotechnology company using advanced nanoparticle drug-delivery technology to unleash the immense potential of next-generation biological and genetic medicine and deliver life-changing therapeutics. QurCan's next generation nanoparticle platform, TERP, enables tissue-selective delivery of nucleotides and biological therapeutics to extra-hepatic sites, including brain and spleen. TERP technology is a breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine that will make a difference to patients with a wide range of unmet medical needs.

Radialis is advancing precision medicine by providing the next generation of organ-targeted positron emission tomography (PET).

Radiant Biotherapeutics: Transformative, multi-valent, multi-specific antibody platform: Multabody Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. The proprietary Multabody platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies have potential to deliver a new class of biologics to tackle complex, heterogenous diseases, such as cancer, that often have challenging targets and mechanisms. Multabody production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. Strategic partnerships with two leading biopharmaceutical companies validate the platform and its broad scientific and clinical utility. For more, visit radiantbio.com.

Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on a novel series of small-molecule DNA-damage response inhibitors. The company focuses on utilizing Deep Docking™ AI to target DNA-damage response (DDR) for oncology-focused treatments. Their target markets include breast cancer, ovarian cancer, and prostate cancer.

Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners have used our technologies to advance their R&D and drug discovery projects, and to publish papers in Nature Biotechnology, mAbs, and other journals.

We are a Canadian publicly traded Canadian life-sciences company that provides innovation, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers quick, convenient precise and discreet™ and smoke-free choices to consumers. RDT is focused on clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to innovative solutions for future market needs — including humans, animals and plants. We are now publicly listed on the Canadian Securities Exchange: $DOSE.

Raspberry Scientific is committed to develop the future of molecular diagnostics with optical technologies to ensure faster, better and more affordable health care for all!

At Rehabtronics, we make technology to help people recover from neurological injuries like stroke and spinal cord injury. Our products include the ReJoyce and ReTouch workstations for upper extremity rehabilitation, and the ReGrasp nerve stimulator for hand movement.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Our company was founded in 2016 by field-leading academics to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines. For more information, please visit www.reparerx.com. Scam Prevention Notice It has come to our attention that individuals posing as representatives of Repare Therapeutics have been engaging in fraudulent recruiting activities, offering fake job opportunities to unsuspecting candidates. These scams are designed to deceive job seekers into providing personal information or financial details under false pretenses. Please note that we will only contact you about a position that is posted on our careers page and official email communications from Repare employees will only come from a @reparerx.com email. Repare has a formal process which includes candidate application through the Repare career page (https://www.reparerx.com/careers/). If the job is not posted on the official Repare Therapeutics careers page, then it is not a legitimate position. If you have any questions or concerns regarding job opportunities at Repare Therapeutics, please don't hesitate to reach out to our HR department directly via Contact Us section (https://www.reparerx.com/contact/). Thank you for your vigilance and understanding.

RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth. RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018. RepliCel's nearest-term commercial asset is its next-generation dermal injector, RCI-02 which represents a medical device bringing unparalleled precision and consistency to dermal injections including shallow, even dispersion of dermal fillers for fine wrinkles. RCI-02 also promises to obviate the need for local anesthetic injections due to its patented skin-numbing element embedded in the device.

Replicor Inc. is a Canadian biotechnology company focused on the development of its nucleic acid polymer (NAP) technology for the treatment of hepatitis B (HBV) and delta (HDV) infections. NAPs are the only antiviral agent to directly target the immunosuppressive protein (HBsAg) which drives chronic HBV infection and liver disease. Our lead clinical NAP drug product is REP 2139-Mg, a proprietary formulation of REP 2139 which makes once weekly subcutaneous injections easily tolerated. Replicor's latest clinical data demonstrates that NAP-based combination therapy can restore immune control of HBV infection in 78% of patients and eliminate HDV infection in 74% of patients. These effects persist in the absence of any therapy, allowing the liver to heal. REP 2139-Mg based combination promises to revolutionize the therapy of chronic HBV and HDV infection and play a pivotal role in the WHO's goal of eliminating viral hepatitis by 2030.

RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec's proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer's disease. RetiSpec is involved in multiple Alzheimer's and brain health studies in leading hospitals and research networks throughout North America. RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer's disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimer's Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a new innovating solution to fight infections.0

Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

Sernova (TSX: SVA) (OTCQB: SEOVF) is a clinical-stage biotechnology company that is advancing a novel cell therapy platform for the treatment of chronic diseases. Our lead program is evaluating our Cell Pouch System™ as a potential ‘functional cure’ for insulin-dependent diabetes. In addition, we have a robust pipeline that includes preclinical programs in hemophilia A and hypothyroidism.

Carisma Therapeutics Closes Merger with Sesen Bio (3/7/23) Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" We are passionate in our commitment to improving and renewing people's lives. Sesen Bio is a late-stage company developing fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body’s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium’s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors. The first assessment of this is in a clinical study combing Vicinium with AstraZeneca’s durvalumab, in NMIBC. For more information, please visit www.sesenbio.com.

SignalChem Lifesciences - Headquartered in British Columbia, Canada, SignalChem was established in 2004 and became a global leader in cell signaling and protein engineering. The company employs 60 scientists and consists of four business units. SignalChem’s Bioreagent unit generates worldwide, annual sales expected to reach ~$8M this year. This unit’s success has enabled the Drug Discovery unit to remain non-diluted and self-funded. The Drug Discovery unit includes five projects in various stages of development benefiting from the company’s core expertise and knowledge. SLC-391 (a potent and selective AXL inhibitor) is its most advanced program in late-Phase I clinical development. SignalChem is now entering its first-ever round of financing, seeking $20M to complete Phase II clinical development in oncology, which is planned to start in Q1, 2022. SignalChem is open to a variety of business/financial models to support our efforts to bring SLC-391 to patients suffering from Cancer. To learn more about SLC-391, join us for a partnering meeting or attend our conference presentation. We look forward to meeting you.

We address the inefficiency of clinical trial success that is currently at >90% failure rate. Simmunome is at the leading edge of leveraging AI towards unraveling biological complexity. We transform physiological systems into biologically representative computational models for use in therapeutic and preventative drug discovery. Despite the significant technological advances in biotechnology, high-throughput methods, and computational biology over the last 20 years, it has proven difficult to gain meaningful insights that translate into truly disruptive medicines. We combine fragmented data to create holistic models of disease that translate to helping you understand your drug's mechanism of action, increase efficacy in the right target population and predict your drug's safety profile. Ultimately getting you to market faster, reducing your R&D costs, and dramatically increasing your probability of success.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem (located in France) is the recipient of multiple French scientific awards and European Union and French government grants. Sirona Biochem is a publicly-traded company. The company is listed on the TSX Venture Exchange in Canada under the symbol SBM, the OTC Pink Sheets in the United States under the symbol SRBCF and in Frankfurt under the symbol ZSB.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental illness, neurological and pain disorders.

Soricimed is a privately-held, clinical stage company dedicated to developing effective and novel targeted treatments for cancer. Since the discovery of a unique protein found in the venomous saliva of the northern short-tailed shrew in 2005, the company is committed to developing effective, highly targeted delivery peptides and powerful therapeutics for several types of solid tumour cancers, making an impact on those living with often devastating conditions. General Information and Guidelines: Soricimed strives to create informative and engaging online communities that share information in meaningful ways. We welcome and encourage your participation and engagement in thoughtful and respectful discourse.

Spiderwortisdeveloping a novel biomaterial that will offer new avenues in 3D in vitro research and in regenerative medicineusing plant derived cellulose to create a variety of scaffold architectures.

Headquartered in Ontario, Canada, SpinaFX is working to introduce minimally invasive, image-guided solutions to the market that benefit patients, physicians, facilities and payers. SpinaFX Medical's flagship treatment solution involves the intravertebral injection of a mixture of oxygen and ozone gas into a contained herniated disc for relief of back and leg pain. This technology is not currently approved for sale by regulatory agencies in the U.S., Canada, EU or elsewhere.

Starpax Biopharma Inc. has developed a novel Precision 3D Guidance Therapy of Magnetodrones™ in tumors. Magnetodrones™ are unique medication-bearing bacteria, developed by Starpax™, that are sensitive to magnetic fields. They deliver the medication into the mass of the tumour, without allowing the medication to circulate in the bloodstream. At the same time, the Magnetodrones™ saturate hypoxic areas where cancerous cells are difficult to reach with other treatments. Magnetodrones are injected directly into the tumour and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak™ prevents the Magnetodrones™ from leaving the tumour and guides them in 3D with special magnetic fields. Starpax Biopharma inc. a développé une thérapie inédite de guidage de précision 3D de Magnétodrones™ dans les tumeurs.. Les Magnétodrones™ sont des bactéries uniques développées par Starpax, sensibles aux champs magnétiques, sur lesquelles sont attachés les médicaments à leur surface. Les Magnétodrones™ distribuent des médicaments dans la masse des tumeurs sans circuler dans le réseau sanguin, tout en saturant les zones hypoxiques où les cellules cancéreuses sont difficiles à atteindre par le biais d'autres traitements. Les Magnétodrones™ sont injectés directement dans la tumeur et guidés par l'appareil PolarTrak™, où le patient est installé. Le PolarTrak™ empêche les Magnétodrones™ de sortir de la tumeur et les guide en 3D grâce à ses champs magnétiques spéciaux.

Syantra Inc. is a precision healthcare company changing the way cancer is detected and treated, starting with breast cancer. Learn about Syantra DX | Breast Cancer. A blood test for breast cancer screening that's easy, convenient and accurate.

SYNG Pharmaceuticals Inc. (SYNG Pharma) is a pre-clinical stage biotechnology company dedicated to developing next generation diagnostic and therapeutic against endometriosis. The company is developing a novel peptide, SP011, to inhibit a target now known for its role in the proliferation of cells. SYNG Pharma has a potential to develop a treatment that would be a much needed alternative to currently available, partly ineffective, hormonal therapy. There are many other potential applications of SYNG Pharma technology including the treatment of fibroids and uterine sarcoma; breast and prostate cancer which may be further developed depending upon corporate interests and an opportunity for partnership.

Synucure Therapeutics inc. is a Canadian biotechnology company conducting research in brain degenerative disorders. Synucure was founded in 2021 with the key objective to pursue the promising and robust pre-clinical work of Dr. Francesca Cicchetti on a repurposed drug called Cysteamine which demonstrated, in various animal and cell models, that the drug could prevent and/or reverse a number of features related to Parkinson’s Disease (PD). Her research on the potential benefits of Cysteamine in neurodegenerative disorders was initiated 20 years ago. In addition to the promising role of Cysteamine as a Disease Modifying Therapy (DMT) in Parkinson, Dr. Cicchetti and her colleagues conducted research on patented blood biomarkers, of which the main objective is to provide clinicians with a more precise diagnostic and stratification tool for the disease using a simple blood test. If you need more information, please contact us at info@synucure.com

Theralase® is focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive applications. The company is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (PDCs) for the treatment of various cancers. Theralase® was one of the first companies in North America to develop personalized anti-cancer therapy and cool laser therapy.

Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The company currently markets two medicines in HIV and has research programs in HIV, NASH, and Oncology.

Translatum Medicus Inc is a preclinical drug development company focused on macrophage modulation to treat blinding eye disease, with a patented lead drug candidate, TMi-018 for the treatment of dry Age-Related Macular Degeneration (AMD). Translatum is based in the Johnson & Johnson Innovation Incubator JLABS@Toronto, and has been increasingly gaining traction as one of the most innovative early stage ophthalmic biotech companies.

Valence Labs is a biotechnology company that specializes in AI-driven drug discovery. It operates as a semi-autonomous research and productization engine within Recursion Pharmaceuticals. The company focuses on leveraging deep learning applications to enhance drug development, particularly for complex diseases. Valence Labs develops software tools that accelerate therapeutic research, including novel target identification and molecular design. In addition to its AI-driven initiatives, Valence Labs is associated with a separate entity that specializes in active pharmaceutical ingredient (API) synthesis. This division offers custom API manufacturing services, including process development and GMP-compliant commercial-scale production. Valence Labs collaborates with biotech partners to provide AI solutions, emphasizing complex chemistry and preclinical optimization.

Verity Pharmaceuticals is a specialty pharmaceutical company that focuses on commercializing therapeutically relevant prescription medicines that are in short supply or absent from the Canadian health care environment. Verity Pharmaceuticals is managed by experienced pharmaceutical executives and guided by a globally recognized scientific advisory board.

To strengthen Canada’s role in responding to infectious diseases, the University of Saskatchewan's Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) works with international partners to study human and animal pathogens and develop solutions.With 150 interdisciplinary personnel, over $200 million in containment infrastructure, and more

Virogin Biotech is a biotechnology company that specializes in oncolytic virus drug development to create impactful drugs for patients with the highest medical need.

Voyageur Pharmaceuticals Ltd. | VM.TSX Voyageur Pharmaceuticals Ltd. is an entrepreneurial driven company headquartered in Canada, specializing in the development and manufacturing of natural based contrast agents for diagnostic imaging technologies. Our trading symbol is VM.TSX on the Toronto Venture Exchange, testament to our robust corporate positioning and transparent operations. Our primary offerings span across the realms of CT, Fluoroscopy, MRI, and Ultrasound imaging. We proudly source Barium and Iodine directly from the earth, rigorously purifying these minerals into Active Pharmaceutical Ingredients (APIs), before culminating the process in the creation of finished drug products. This complete, end-to-end production chain aligns seamlessly with our motto - "From the Earth to the Bottle". On the frontier of innovation, Voyageur Pharmaceuticals is also actively engaged in Fullerene drug development. This remarkable technology harnesses the potential of carbon capture through the Eden system, turning captured carbon into Fullerenes, thus laying the groundwork for a new, revolutionary drug development program. Our operations are rooted in a scientific and drug-oriented focus, keeping patient well-being and improved diagnostic accuracy at the heart of our mission. Committed to excellence and innovation, Voyageur Pharmaceuticals Ltd. is not just about mining resources; it's about mining the future of healthcare. We invite you to connect with us, be part of our story, and explore the boundless opportunities that lie at the intersection of nature, science, and technology.

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

XORTX Therapeutics Inc. is a late stage clinical pharmaceutical company dedicated to developing new therapies for progressive kidney disease. The company has two clinically advanced products in development, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XORTX Therapeutics Inc. is also focused on developing innovative therapies to treat progressive kidney disease, with three drug development programs, two of which are clinically advanced products under development.

Developing partial reprogramming gene therapies

Zilia is a health technology company developing a breakthrough platform to measure biomarkers in the eye, with an initial focus on ocular oximetry.

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life..

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025.